The present study of the regulatory T phenotype of Sézary cells led to the discovery of the expression of CD1a by Sézary cells. CD1a therefore appears as a diagnostic marker for monitoring Sézary syndrome and as a therapeutic target. Accordingly, the present invention relates to methods for the diagnosis and treatment of cutaneous T cell-lymphomas.